Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.55 |
| ▸ | HPGD | P15428 | 5/20 | 0.55 |
| ▸ | HSD17B10 | Q99714 | 5/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | ATM | Q13315 | 1/20 | 0.43 |
| ▸ | CA12 | O43570 | 1/20 | 0.43 |
| ▸ | CA1 | P00915 | 1/20 | 0.43 |
| ▸ | CA2 | P00918 | 1/20 | 0.43 |
| ▸ | CA4 | P22748 | 1/20 | 0.43 |
| ▸ | CA6 | P23280 | 1/20 | 0.43 |
| ▸ | CA7 | P43166 | 1/20 | 0.43 |
| ▸ | TPMT | P51580 | 1/20 | 0.43 |
| ▸ | CA9 | Q16790 | 1/20 | 0.43 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.43 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.43 |
| ▸ | NQO2 | P16083 | 2/20 | 0.43 |
| ▸ | SRD5A1 | P18405 | 1/20 | 0.42 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26581211 | 0.89 | HPGD (0.51) | KMT2AKDM4EHPGDHSD17B10ALDH1A1 | |
| SCHEMBL2326863 | 0.78 | CCR2 (0.55) | KDM4EHPGDHSD17B10ALDH1A1SMN1; SMN2 | |
| SCHEMBL3747639 | 0.78 | KDM4E (0.60) | KDM4EHPGDHSD17B10ALDH1A1SMN1; SMN2 | |
| SCHEMBL645633 | 0.77 | KMT2A (0.55) | KMT2AKDM4EHPGDHSD17B10ALDH1A1 | |
| SCHEMBL26580392 | 0.75 | KDM4E (0.61) | KMT2AKDM4EHPGDHSD17B10ALDH1A1 | |
| SCHEMBL26581395 | 0.75 | KMT2A (0.43) | KMT2AKDM4EHPGDHSD17B10ALDH1A1 | |
| SCHEMBL19332265 | 0.75 | KDM4E (0.51) | KMT2AKDM4EHPGDHSD17B10ALDH1A1 | |
| SCHEMBL30339456 | 0.75 | KDM4E (0.51) | KMT2AKDM4EHPGDHSD17B10ALDH1A1 | |
| SCHEMBL23809499 | 0.75 | KDM4E (0.47) | KMT2AKDM4EHPGDHSD17B10ALDH1A1 | |
| SCHEMBL23800686 | 0.74 | KMT2A (0.45) | KMT2AKDM4EHPGDHSD17B10ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120108630-A1 | Hedgehog Pathway Antagonists and Methods of Use | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2012-05-03 | — | — | US | disclosed |
| US-8119640-B2 | Hedgehog pathway antagonists methods of use | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2012-02-21 | — | — | US | disclosed |
| US-20110015201-A1 | HEDGEHOG PATHWAY ANTAGONISTS AND METHODS OF USE | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2011-01-20 | — | — | US | disclosed |
| EP-2249818-A1 | HEDGEHOG PATHWAY ANTAGONISTS AND METHODS OF USE | Stanford University (US) | 2010-11-17 | — | — | EP | disclosed |
| WO-2009102864-A1 | HEDGEHOG PATHWAY ANTAGONISTS AND METHODS OF USE | STANFORD UNIVERSITY (US) | 2009-08-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110015201-A1 | HEDGEHOG PATHWAY ANTAGONISTS AND METHODS OF USE | SHH, GLI1, SMO | KMT2A 1244/4885KDM4E 1642/4885HPGD 3250/4885 |
| US-20120108630-A1 | Hedgehog Pathway Antagonists and Methods of Use | SHH, GLI1, SMO | KMT2A 1244/4885KDM4E 1642/4885HPGD 3250/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.